Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.06
HSIC's Cash to Debt is ranked lower than
93% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.71 vs. HSIC: 0.06 )
Ranked among companies with meaningful Cash to Debt only.
HSIC' s 10-Year Cash to Debt Range
Min: 0.04  Med: 0.34 Max: N/A
Current: 0.06
Equity to Asset 0.47
HSIC's Equity to Asset is ranked higher than
57% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.43 vs. HSIC: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
HSIC' s 10-Year Equity to Asset Range
Min: 0.42  Med: 0.51 Max: 0.67
Current: 0.47
0.42
0.67
Interest Coverage 29.73
HSIC's Interest Coverage is ranked lower than
56% of the 27 Companies
in the Global Medical Distribution industry.

( Industry Median: 79.78 vs. HSIC: 29.73 )
Ranked among companies with meaningful Interest Coverage only.
HSIC' s 10-Year Interest Coverage Range
Min: 4.68  Med: 10.99 Max: 29.73
Current: 29.73
4.68
29.73
F-Score: 6
Z-Score: 5.19
M-Score: -2.62
WACC vs ROIC
9.02%
14.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 6.92
HSIC's Operating margin (%) is ranked higher than
66% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.95 vs. HSIC: 6.92 )
Ranked among companies with meaningful Operating margin (%) only.
HSIC' s 10-Year Operating margin (%) Range
Min: 3.14  Med: 6.30 Max: 7.27
Current: 6.92
3.14
7.27
Net-margin (%) 4.50
HSIC's Net-margin (%) is ranked higher than
63% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.84 vs. HSIC: 4.50 )
Ranked among companies with meaningful Net-margin (%) only.
HSIC' s 10-Year Net-margin (%) Range
Min: -0.13  Med: 3.53 Max: 4.76
Current: 4.5
-0.13
4.76
ROE (%) 16.66
HSIC's ROE (%) is ranked higher than
72% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 9.65 vs. HSIC: 16.66 )
Ranked among companies with meaningful ROE (%) only.
HSIC' s 10-Year ROE (%) Range
Min: -0.53  Med: 13.48 Max: 16.65
Current: 16.66
-0.53
16.65
ROA (%) 7.74
HSIC's ROA (%) is ranked higher than
80% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 4.31 vs. HSIC: 7.74 )
Ranked among companies with meaningful ROA (%) only.
HSIC' s 10-Year ROA (%) Range
Min: -0.31  Med: 6.93 Max: 8.37
Current: 7.74
-0.31
8.37
ROC (Joel Greenblatt) (%) 44.84
HSIC's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 21.16 vs. HSIC: 44.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HSIC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.37  Med: 41.40 Max: 51.27
Current: 44.84
6.37
51.27
Revenue Growth (3Y)(%) 9.50
HSIC's Revenue Growth (3Y)(%) is ranked higher than
55% of the 31 Companies
in the Global Medical Distribution industry.

( Industry Median: 6.80 vs. HSIC: 9.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HSIC' s 10-Year Revenue Growth (3Y)(%) Range
Min: 4.5  Med: 9.60 Max: 34.8
Current: 9.5
4.5
34.8
EBITDA Growth (3Y)(%) 10.10
HSIC's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 30 Companies
in the Global Medical Distribution industry.

( Industry Median: 9.40 vs. HSIC: 10.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HSIC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 8.3  Med: 12.60 Max: 89.5
Current: 10.1
8.3
89.5
EPS Growth (3Y)(%) 11.10
HSIC's EPS Growth (3Y)(%) is ranked higher than
59% of the 29 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.50 vs. HSIC: 11.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HSIC' s 10-Year EPS Growth (3Y)(%) Range
Min: 6.1  Med: 12.20 Max: 69.3
Current: 11.1
6.1
69.3
» HSIC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

HSIC Guru Trades in Q3 2014

Jim Simons 52,206 sh (New)
Ray Dalio 2,250 sh (New)
Paul Tudor Jones 6,900 sh (+15.00%)
Ken Fisher 534,025 sh (-1.65%)
Mario Gabelli 207,141 sh (-3.07%)
Jeremy Grantham 221,978 sh (-4.76%)
Ron Baron 409,429 sh (-9.82%)
Columbia Wanger 883,500 sh (-12.31%)
» More
Q4 2014

HSIC Guru Trades in Q4 2014

Jeremy Grantham 265,646 sh (+19.67%)
Ron Baron 409,509 sh (+0.02%)
Jim Simons Sold Out
Ray Dalio Sold Out
Ken Fisher 533,607 sh (-0.08%)
Mario Gabelli 202,841 sh (-2.08%)
Paul Tudor Jones 6,500 sh (-5.80%)
Columbia Wanger 392,800 sh (-55.54%)
» More
Q1 2015

HSIC Guru Trades in Q1 2015

Columbia Wanger 391,800 sh (-0.25%)
Ron Baron 408,263 sh (-0.30%)
Ken Fisher 530,109 sh (-0.66%)
Mario Gabelli 200,180 sh (-1.31%)
Jeremy Grantham 259,382 sh (-2.36%)
Paul Tudor Jones 6,200 sh (-4.62%)
» More
Q2 2015

HSIC Guru Trades in Q2 2015

Ken Fisher 528,144 sh (-0.37%)
» More
» Details

Insider Trades

Latest Guru Trades with HSIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.83
HSIC's P/E(ttm) is ranked lower than
53% of the 30 Companies
in the Global Medical Distribution industry.

( Industry Median: 24.40 vs. HSIC: 26.83 )
Ranked among companies with meaningful P/E(ttm) only.
HSIC' s 10-Year P/E(ttm) Range
Min: 12.03  Med: 21.97 Max: 35.43
Current: 26.83
12.03
35.43
Forward P/E 21.98
HSIC's Forward P/E is ranked lower than
74% of the 19 Companies
in the Global Medical Distribution industry.

( Industry Median: 17.01 vs. HSIC: 21.98 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 26.60
HSIC's PE(NRI) is ranked lower than
53% of the 30 Companies
in the Global Medical Distribution industry.

( Industry Median: 24.40 vs. HSIC: 26.60 )
Ranked among companies with meaningful PE(NRI) only.
HSIC' s 10-Year PE(NRI) Range
Min: 12.02  Med: 21.49 Max: 32.37
Current: 26.6
12.02
32.37
P/B 4.32
HSIC's P/B is ranked lower than
73% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.54 vs. HSIC: 4.32 )
Ranked among companies with meaningful P/B only.
HSIC' s 10-Year P/B Range
Min: 1.57  Med: 2.85 Max: 4.39
Current: 4.32
1.57
4.39
P/S 1.21
HSIC's P/S is ranked lower than
57% of the 42 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.10 vs. HSIC: 1.21 )
Ranked among companies with meaningful P/S only.
HSIC' s 10-Year P/S Range
Min: 0.48  Med: 0.85 Max: 1.21
Current: 1.21
0.48
1.21
PFCF 22.78
HSIC's PFCF is ranked lower than
52% of the 23 Companies
in the Global Medical Distribution industry.

( Industry Median: 20.78 vs. HSIC: 22.78 )
Ranked among companies with meaningful PFCF only.
HSIC' s 10-Year PFCF Range
Min: 9.15  Med: 19.11 Max: 34.35
Current: 22.78
9.15
34.35
POCF 19.95
HSIC's POCF is ranked lower than
58% of the 31 Companies
in the Global Medical Distribution industry.

( Industry Median: 15.76 vs. HSIC: 19.95 )
Ranked among companies with meaningful POCF only.
HSIC' s 10-Year POCF Range
Min: 7.99  Med: 16.01 Max: 23.17
Current: 19.95
7.99
23.17
EV-to-EBIT 17.78
HSIC's EV-to-EBIT is ranked lower than
57% of the 30 Companies
in the Global Medical Distribution industry.

( Industry Median: 16.44 vs. HSIC: 17.78 )
Ranked among companies with meaningful EV-to-EBIT only.
HSIC' s 10-Year EV-to-EBIT Range
Min: 7.3  Med: 14.20 Max: 20.5
Current: 17.78
7.3
20.5
PEG 2.44
HSIC's PEG is ranked higher than
50% of the 20 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.47 vs. HSIC: 2.44 )
Ranked among companies with meaningful PEG only.
HSIC' s 10-Year PEG Range
Min: 0.53  Med: 2.02 Max: 3.4
Current: 2.44
0.53
3.4
Shiller P/E 31.88
HSIC's Shiller P/E is ranked higher than
52% of the 25 Companies
in the Global Medical Distribution industry.

( Industry Median: 32.24 vs. HSIC: 31.88 )
Ranked among companies with meaningful Shiller P/E only.
HSIC' s 10-Year Shiller P/E Range
Min: 16.87  Med: 27.59 Max: 37.15
Current: 31.88
16.87
37.15
Current Ratio 1.78
HSIC's Current Ratio is ranked higher than
65% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.64 vs. HSIC: 1.78 )
Ranked among companies with meaningful Current Ratio only.
HSIC' s 10-Year Current Ratio Range
Min: 1.64  Med: 2.19 Max: 2.98
Current: 1.78
1.64
2.98
Quick Ratio 0.97
HSIC's Quick Ratio is ranked lower than
68% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.26 vs. HSIC: 0.97 )
Ranked among companies with meaningful Quick Ratio only.
HSIC' s 10-Year Quick Ratio Range
Min: 0.89  Med: 1.39 Max: 2.1
Current: 0.97
0.89
2.1
Days Inventory 63.34
HSIC's Days Inventory is ranked lower than
68% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 49.37 vs. HSIC: 63.34 )
Ranked among companies with meaningful Days Inventory only.
HSIC' s 10-Year Days Inventory Range
Min: 53.33  Med: 56.60 Max: 65.9
Current: 63.34
53.33
65.9
Days Sales Outstanding 40.79
HSIC's Days Sales Outstanding is ranked higher than
68% of the 37 Companies
in the Global Medical Distribution industry.

( Industry Median: 53.74 vs. HSIC: 40.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
HSIC' s 10-Year Days Sales Outstanding Range
Min: 34.72  Med: 45.55 Max: 64.18
Current: 40.79
34.72
64.18

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 31.69
HSIC's Price/Tangible Book is ranked lower than
97% of the 36 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.25 vs. HSIC: 31.69 )
Ranked among companies with meaningful Price/Tangible Book only.
HSIC' s 10-Year Price/Tangible Book Range
Min: 2.37  Med: 5.97 Max: 42.44
Current: 31.69
2.37
42.44
Price/Projected FCF 1.47
HSIC's Price/Projected FCF is ranked lower than
57% of the 23 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.44 vs. HSIC: 1.47 )
Ranked among companies with meaningful Price/Projected FCF only.
HSIC' s 10-Year Price/Projected FCF Range
Min: 0.76  Med: 1.36 Max: 22.69
Current: 1.47
0.76
22.69
Price/DCF (Earnings Based) 1.35
HSIC's Price/DCF (Earnings Based) is ranked lower than
67% of the 6 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.25 vs. HSIC: 1.35 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.42
HSIC's Price/Median PS Value is ranked lower than
63% of the 38 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.27 vs. HSIC: 1.42 )
Ranked among companies with meaningful Price/Median PS Value only.
HSIC' s 10-Year Price/Median PS Value Range
Min: 0.28  Med: 0.92 Max: 1.5
Current: 1.42
0.28
1.5
Price/Peter Lynch Fair Value 2.62
HSIC's Price/Peter Lynch Fair Value is ranked lower than
71% of the 14 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.91 vs. HSIC: 2.62 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
HSIC' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.59  Med: 1.57 Max: 3.33
Current: 2.62
0.59
3.33
Price/Graham Number 5.85
HSIC's Price/Graham Number is ranked lower than
82% of the 28 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.80 vs. HSIC: 5.85 )
Ranked among companies with meaningful Price/Graham Number only.
HSIC' s 10-Year Price/Graham Number Range
Min: 1.08  Med: 2.65 Max: 43.52
Current: 5.85
1.08
43.52
Earnings Yield (Greenblatt) (%) 5.65
HSIC's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.20 vs. HSIC: 5.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HSIC' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 4.9  Med: 7.05 Max: 13.6
Current: 5.65
4.9
13.6
Forward Rate of Return (Yacktman) (%) 13.90
HSIC's Forward Rate of Return (Yacktman) (%) is ranked higher than
54% of the 26 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.33 vs. HSIC: 13.90 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HSIC' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 10.5  Med: 15.80 Max: 29.2
Current: 13.9
10.5
29.2

Business Description

Industry: Medical Distribution » Medical Distribution
Compare:ABC, MCK, CAH, SHTDF, PDCO » details
Traded in other countries:HS2.Germany,
Henry Schein Inc was incorporated in Delaware in December 1992. The Company is engaged in offering a selection of products and services and value-added solutions for operating efficient practices and delivering high quality care. The Company operates through a centralized and automated distribution network with a selection of more than 96,000 branded products and Henry Schein private brand products in stock, as well as more than 110,000 additional products available as special order items. It also offers its customers technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services. The Company conducts its business through two reportable segments: health care distribution and technology and value-added services. The health care distribution reportable segment aggregates its dental, animal health and medical operating segments. This segment consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The Company's technology and value-added services group provides software, technology and other value-added services to health care practitioners. Its technology group offerings include practice management software systems for dental and medical practitioners and animal health clinics. The Company's value-added practice solutions include financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners. The Company's main competitors include the GACD Group, Pluradent AG & Co., Lifco AB, Planmeca Oy, Billericay Dental Supply Co. Ltd., National Veterinary Services and Alcyon SA. The Company's business is subject to local, state, federal and foreign governmental laws and regulations applicable to the distribution of pharmaceuticals and medical devices. The Company's businesses are subject to various additional federal, state, local and foreign laws and regulations, including with respect to the sale, transportation, storage, handling and disposal of hazardous or potentially hazardous substances, and safe working conditions. Its businesses are also subject to requirements of similar and other foreign governmental laws and regulations affecting its operations abroad.
» More Articles for HSIC

Headlines

Articles On GuruFocus.com
Weekly 52-Week Highs Highlight: BCS, RYAAY, MMC, HSIC Jun 14 2015 
Why Hedge Funds Are Betting On AmerisourceBergen Apr 10 2015 
Weekly 52-Week Highs Highlight: DLTR, NTES, HSIC, ADM Nov 23 2014 
AmerisourceBergen Is a Center Piece in the Pharma Industry Sep 30 2014 
Weekly 52-Week Highs Highlight: IHG, HSIC, GGP, AAL Jun 02 2014 
Mario Gabelli on Aging America, Alcohol, Twitter, Facebook Dec 17 2013 
Importance of Leadership in a 5-Star Company Feb 05 2013 
Comment for Buffett-Munger Screener - Good Companies at Fair or Undervalued Prices -- GuruFocus.com Oct 12 2012 
Looking at the Big Picture Apr 25 2012 
Henry Schein Inc. (HSIC) President, COO James P Breslawski sells 46,000 Shares Mar 07 2011 

More From Other Websites
Henry Schein Misses Q2 Earnings by a Penny, Keeps FY View - Analyst Blog Jul 29 2015
Schein (Henry) (HSIC) Earnings Report: Q2 2015 Conference Call Transcript Jul 29 2015
Edited Transcript of HSIC earnings conference call or presentation 29-Jul-15 2:00pm GMT Jul 29 2015
Henry Schein Inc Earnings Call scheduled for 10:00 am ET today Jul 29 2015
Henry Schein's Earnings 'Pretty Solid': CEO Bergman Jul 29 2015
Henry Schein (HSIC) Misses Q2 Earnings and Revenue Estimates - Tale of the Tape Jul 29 2015
HENRY SCHEIN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 29 2015
Henry Schein misses Street 2Q forecasts Jul 29 2015
Henry Schein misses Street 2Q forecasts Jul 29 2015
7:13 am Henry Schein reports EPS in-line, misses on revs; guides FY15 EPS in-line Jul 29 2015
Henry Schein Reports Record Second Quarter Results Jul 29 2015
Stony Brook University School Of Dental Medicine Unveils 'Henry Schein Cares Reception Area' Jul 28 2015
Stony Brook University School Of Dental Medicine Unveils 'Henry Schein Cares Reception Area' Jul 28 2015
Will Henry Schein (HSIC) Surprise Investors with Q2 Earnings? - Analyst Blog Jul 27 2015
Henry Schein Promotes Peter McCarthy to President, Global Animal Health Group Jul 21 2015
Henry Schein Promotes Peter McCarthy to President, Global Animal Health Group Jul 21 2015
Henry Schein To Webcast Second Quarter 2015 Conference Call On Wednesday, July 29, 2015 At 10:00... Jul 15 2015
Henry Schein To Webcast Second Quarter 2015 Conference Call On Wednesday, July 29, 2015 At 10:00... Jul 15 2015
Henry Schein (HSIC) Enters Animal Health Market in Romania - Analyst Blog Jul 13 2015
Henry Schein Invests in Romania's Maravet Jul 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK